clinical trial · NCT07874815
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 2,136
Pulmonary Disease, Chronic ObstructiveEnsifentrinePlaceboStandard of Care (SOC)
brief summary
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.
started
Nov 2, 2026
primary completion
Apr 29, 2029
completion
Apr 29, 2029
last updated
Nov 16, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol